Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

Autor: Dias MH; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Friskes A; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wang S; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Fernandes Neto JM; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Gemert F; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mourragui S; Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center, Utrecht, the Netherlands., Papagianni C; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kuiken HJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mainardi S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Alvarez-Villanueva D; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain., Lieftink C; Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Morris B; Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Dekker A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Dijk E; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wilms LHS; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., da Silva MS; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, SP, Brazil., Jansen RA; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mulero-Sánchez A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Malzer E; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Vidal A; Department of Pathology, University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Xenopat S.L., Parc Cientific de Barcelona (PCB), Barcelona, Spain., Santos C; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, Barcelona, Spain., Salazar R; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, Barcelona, Spain., Wailemann RAM; Center of Toxins, Immune-response and Cell Signaling, Instituto Butantan, São Paulo, Brazil., Torres TEP; Center of Toxins, Immune-response and Cell Signaling, Instituto Butantan, São Paulo, Brazil.; Department of Clinical and Experimental Oncology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil., De Conti G; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Raaijmakers JA; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; University of Iceland, Faculty of Medicine, Reykjavik, Iceland., Yuan S; The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China., Qin W; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Kovach JS; Lixte Biotechnology Holdings, Inc., Pasadena, California., Armelin HA; Center of Toxins, Immune-response and Cell Signaling, Instituto Butantan, São Paulo, Brazil., Te Riele H; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Oudenaarden A; Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center, Utrecht, the Netherlands., Jin H; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Beijersbergen RL; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Villanueva A; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.; Xenopat S.L., Parc Cientific de Barcelona (PCB), Barcelona, Spain., Medema RH; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Jul 01; Vol. 14 (7), pp. 1276-1301.

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers.

Autor: Jansen RA; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Mainardi S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Dias MH; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Bosma A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., van Dijk E; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Selig R; HepaRegeniX GmbH, Tuebingen 72072, Germany., Albrecht W; HepaRegeniX GmbH, Tuebingen 72072, Germany., Laufer SA; Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Tübingen 72074, Germany.; Tübingen Center for Academic Drug Discovery and Development, Tübingen 72074, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' (EXC 2180), Eberhard Karls Universität Tübingen, Tübingen 72076, Germany., Zender L; Tübingen Center for Academic Drug Discovery and Development, Tübingen 72074, Germany.; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies' (EXC 2180), Eberhard Karls Universität Tübingen, Tübingen 72076, Germany.; Department of Medical Oncology and Pneumology, University Hospital Tübingen, Tübingen 72076, Germany.; German Cancer Research Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany., Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2024 Feb 27; Vol. 121 (9), pp. e2319492121. Date of Electronic Publication: 2024 Feb 20.

Diritto del lavoro nelle pubbliche amministrazioni

Autor: Carinci F., Boscati A., Mainardi S.

Trattazione completa del tema, con impostazione organica originale.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::821501d0a5f664882127d2f2379b3b3e
http://hdl.handle.net/11585/853177

L’assetto delle fonti tra legge e contrattazione collettiva

Autor: Mainardi S.

SOMMARIO 1. Il sistema delle fonti e il paradigma di una riforma. Il ruolo della legge. 2. La disciplina legale dei rapporti di lavoro nelle autonomie territoriali. 3. Il rapporto legge/contratto collettivo e gli ambiti della contrattazione collettiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::c1d19d943faefc4021867b179fce729f
http://hdl.handle.net/11585/853400

Sub art. 2129 c.c. (rinvio)

Autor: Mainardi S.

Commento giuridico (per rinvio)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::123c12b4a2c97a5564b1c4e93cc450b6
http://hdl.handle.net/11585/722923